Clinical trials: Graft Rejection
Graft Rejection, Kidney Disease
Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants
This protocol facilitates the development of methods for determining whether transplant recipients have developed immune hyporesponsiveness or tolerance towards their allograft.
- Trial name
- NCT00001858
- Where
- United States
- Volunteers
- 294 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Influenza
Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in UK
This study aims to assess the risk of solid organ transplant (SOT) rejection following vaccination with Pandemrix™ and/ or seasonal influenza vaccination.
- Trial name
- NCT01715792
- Testing
- Data collection
- Where
- United Kingdom
- Volunteers
- 587 people
- Sponsor
- GlaxoSmithKline
Lung Transplantation Rejection
Prospective Lung Transplant Database for Genetic Research
This study will create a database of clinical and biological research for use in future studies, with information obtained from lung transplant recipients.
- Trial name
- NCT00339209
- Where
- 2 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Corneal Endothelial Dystrophy, Corneal Edema
Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
The purpose of this study is to assess off-label use of loteprednol etabonate 0.25% ophthalmic suspension (Eysuvis) for prevention of immunologic rejection in the first year after Descemet membrane endothelial keratoplasty…
- Trial name
- NCT05136443
- Testing
- loteprednol etabonate 0.25% ophthalmic suspension
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Price Vision Group
Solid Organ Transplant Rejection, Chronic Kidney Failure
Exercise Training and Kidney Transplantation
The goal of this clinical trial is to investigate the physiological and molecular effects of exercise training in transplant recipients. The main questions it aims to answer are: 1.
- Conditions
- Solid Organ Transplant Rejection, Chronic Kidney Failure, Quality of Life, Inflammation
- Trial name
- EXTRA (NCT06216015)
- Testing
- Exercise training, Continue exercising, Discontinue exercising
- Volunteers
- 345 people
- Sponsor
- Hugo de Luca Correa
Kidney Transplant Rejection
An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR
The aim of this trial is to collect data and provide a better understanding of the long-term outcome of imlifidase treatment on active or chronic active antibody-mediated rejection (AMR) in kidney transplant recipients.
- Trial name
- NCT04711850
- Testing
- Imlifidase
- Where
- 7 sites in Austria, France and 1 more
- Volunteers
- 18 people
- Sponsor
- Hansa Biopharma AB
Grafting, Renal Transplantation
Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation
To evaluate the benefit of rituximab in patients with CAN with histologically proven C4d deposits and/or plasma cell and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts.
- Conditions
- Grafting, Renal Transplantation, Transplantation, Kidney, Chronic Allograft Nephropathy
- Trial name
- Rituximab 2006 (NCT00568477)
- Testing
- MabThera
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Technical University of Munich
Cardiac Transplant Rejection
The "no Biopsy Approach" for Heart Transplantation Follow-up
Pathological analysis is the gold standard for diagnosis of acute allograft rejection after heart transplantation (HTx). This method requires repeated endomyocardial biopsies during the first post-operative year.
- Trial name
- NCT03959579
- Testing
- systematic endomyocardial biopsy.
- Where
- France
- Volunteers
- 269 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Kidney Transplant Rejection, Plasmapheresis
The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant
At present, the number of end-stage kidney disease patients is increasing. Kidney transplant surgery is one of the treatments that give patients a better survival rate than hemodialysis or abdominal dialysis.
- Conditions
- Kidney Transplant Rejection, Plasmapheresis, Kidney Replacement
- Trial name
- NCT03965559
- Testing
- plasmapheresis
- Volunteers
- 30 people
- Sponsor
- Chiang Mai University
Kidney Transplant; Complications, Kidney Transplant Rejection
Immunosuppression Reduction in Failed Allograft Guided by cfDNA
The optimal timing for immunosuppression tapering for patients with failed kidney transplant is not known. This pilot study would be to correlate rise in cf-DNA and increase in cPRA.
- Conditions
- Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure
- Trial name
- NCT04560582
- Testing
- Blood Draw
- Where
- United States
- Sponsor
- University of Minnesota
Cardiac Allograft Vasculopathy, Heart Transplant Rejection
Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy
Heart transplantation is a golden standard for the treatment of terminal heart failure. The major cause of death in late posttransplant period is cardiac allograft vasculopathy (CAV).
- Trial name
- ECP-OCT (NCT04226521)
- Testing
- Extracoropreal photopheresis
- Where
- Croatia
- Volunteers
- 38 people
- Sponsor
- Bosko Skoric
Kidney Transplant Rejection
Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants
The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of human leukocyte antigen (HLA)-matched, living…
- Trial name
- NCT03363945
- Testing
- MDR-101
- Where
- 19 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Medeor Therapeutics, Inc.
Complication of Transplanted Liver
Donor Specific HLA Alloantibodies in Liver Transplantation
The aim is to evaluate the impact of donor specific HLA alloantibodies (DSA) on all-cause mortality and re-transplantation, early allograft dysfunction, acute and chronic rejection, fibrosis, vascular, and biliary complications.
- Trial name
- NCT02784080
- Testing
- HLA-alloantibodies exposure
- Where
- 5 sites in Denmark, Finland and 2 more
- Volunteers
- 858 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Heart Transplant Rejection
Prospera Test Evaluation in Cardiac Transplant (ProTECT)
The ProTECT registry is an observational longitudinal, multi-center study observing patients undergoing heart transplant for whom Prospera testing is part of routine clinical care, who are enrolled within 60 days of heart…
- Trial name
- ProTECT (NCT05205551)
- Where
- United States
- Volunteers
- 411 people
- Sponsor
- Natera, Inc.
Lung Transplantation
Can Immune Parameters Predict Acute and Chronic Rejection in Lung Recipients?
This study will evaluate the ability of lung transplant recipients to react to the transplanted organs. Previous research indicates that some immune tests can identify whether people are at risk for chronic rejection of…
- Trial name
- NCT00340951
- Where
- 2 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Kidney Diseases, Graft Rejection
Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)
The main aim of this study is to compare the renal function (serum creatinine at 6 months) in the later introduction of tacrolimus or rapamycin based in immunosuppressor regimes with daclizumab, mycophenolate mofetil, and…
- Trial name
- NCT00290069
- Testing
- Tacrolimus, Rapamycin
- Where
- 7 sites in Spain
- Volunteers
- 94 people
- Sponsor
- Sociedad Andaluza de Trasplantes de Organos y Tejidos
Disorder Related to Renal Transplantation, Renal Transplant Rejection
A Perspective Multicenter Controlled Study On Application Of Mesenchymal Stem Cell(MSC) To Prevent Rejection After Renal Transplantation By Donation After Cardiac Death
Although donation after cardiac death(DCD) is the major source of renal transplantation in China, high incidence rate of rejection and delayed graft function(DGF) is existing due to the prolonged ischemia time.
- Trial name
- NCT02490020
- Testing
- mesenchymal stem cell
- Volunteers
- 260 people
- Sponsor
- Qipeng Sun
Chronic Rejection of Cardiac Transplant
Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up
The different mechanisms of action of Everolimus and cyclosporine suppress immune function in synergistic manner. Thus it is postulated that the use of Everolimus in combination with cyclosporine permits a significant…
- Trial name
- CRAD001AILO2 (NCT00596557)
- Testing
- everolimus
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Rabin Medical Center
Renal Transplant Failure and Rejection, Hypotension
HOW DOES HEMODYNAMIC REGULATION AFFECTS GRAFT FUNCTIONS DURING RENAL TRANSPLANTATION?
The aim of the researchers was to evaluate the adequacy of graft function in the postoperative period of patients who underwent renal transplantation and encountered hypotension in the intraoperative period.
- Trial name
- NCT05753475
- Testing
- renal transplantation
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ankara City Hospital Bilkent
Renal Transplant Rejection, Pediatric Kidney Disease
VIRTUUS Children's Study
The objective of the VIRTUUS Children's Study is to adapt identified and validated adult noninvasive diagnostic and prognostic biomarkers for the characterization of allograft status in pediatric recipients of kidney allografts.
- Conditions
- Renal Transplant Rejection, Pediatric Kidney Disease, End Stage Renal Disease, Nephropathy
- Trial name
- VIRTUUS (NCT03719339)
- Where
- 13 sites in United States, Canada
- Volunteers
- 445 people
- Sponsor
- Children's Hospital of Philadelphia